Curis Q3 loss per share narrows as operating expenses fall

Overview

• US biotechnology firm's Q3 net loss per share narrowed, beating analyst expectations

• Company reported no revenue for Q3 after sale of Erivedge royalties in late 2025

• Research and administrative expenses declined yr/yr, mainly due to lower employee-related costs

Outlook

• Curis expects initial data from TakeAim CLL study in December 2026

• Company says cash and recent financing should fund operations into Q1 2027

• Curis expects ongoing TakeAim Lymphoma study could support regulatory applications for accelerated approval

Result Drivers

• NO REVENUE - Co reported no revenue in Q3 2026 due to sale of Erivedge royalties in Q4 2025

• LOWER OPERATING EXPENSES - Research and development and general and administrative expenses declined yr/yr, mainly due to lower employee-related costs

• OTHER INCOME - Increase in other income driven by change in fair value of warrant liability from January 2026 private placement

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Curis Inc is $43.00, about 7,169.7% above its November 11 closing price of $0.59

Reuters Recommended Reads

• Nov 12 - 4D Molecular Therapeutics Q3 net loss widens on higher costs

• Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs

• Nov 10 - Cellectar Biosciences Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)